



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Bernd RIEDL et al.

COPY

Serial No.: TO BE ASSIGNED

Group Art Unit: TO BE ASSIGNED

Filed: November 27, 2000

Examiner: TO BE ASSIGNED

For: ω -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Pursuant to 37 CFR §1.97 and §1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Applicants also identifies the following related copending applications.

	<u>Serial Number</u>	<u>Filing Date</u>	<u>Title</u>
Bayer 1	08/863,021	May 23, 1997	RAF Kinase Inhibitors
Bayer 2	08/863,022	May 23, 1997	RAF Kinase Inhibitors
Bayer 6 P1	Unassigned	December 22, 1998	Inhibition of RAF Kinase Using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas
Bayer 8 C1	09/640,780	August 18, 2000	Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas
Bayer 9 C1	09/472,232	December 27, 1998	Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
Bayer 10 C1	09/458,015	December 10, 1999	Inhibition of P38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas